Results 231 to 240 of about 10,059 (251)

Anidulafungin was noninferior to fluconazole for invasive candidiasis

ACP Journal Club, 2008
Source Citation Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med.
openaire   +3 more sources

Anidulafungin: a new echinocandin for candidal infections

Expert Review of Anti-infective Therapy, 2007
Anidulafungin, a new echinocandin, has recently been approved for the treatment of esophageal candidiasis, candidemia and other forms of invasive candidiasis, such as peritonitis and intra-abdominal abscesses in non-neutropenic patients. It is fungicidal against Candida spp.
Annette C. Reboli, Pola de la Torre
openaire   +3 more sources

Anidulafungin in the treatment of patients with invasive candidiasis

International Journal of Antimicrobial Agents, 2008
Echinocandins have emerged as important agents for the treatment of invasive candidiasis. Forthcoming guidelines are expected to recommend an echinocandin agent as initial primary therapy in patients who are severely ill and/or have risk factors for azole resistance.
Daniel H. Kett, G Fernando Cubillos
openaire   +3 more sources

Anidulafungin: A Novel Echinocandin for Candida Infections

Future Microbiology, 2008
A third echinocandin, anidulafungin, has recently been approved for Candida infections in the non-neutropenic patient. In the EU it is indicated for invasive candidiasis; in 2006 it was approved in the USA for candida esophagitis, candidemia, and two types of invasive infections, peritonitis and intra-abdominal abscesses.
Annette C. Reboli, Daniel K Meyer, Pola de la Torre   +2 more
openaire   +3 more sources

Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia

Journal of Chemotherapy, 2010
Candida species are the most common causes of invasive fungal infections in humans, producing infections that range from mucocutaneous disorders to invasive disease that can involve any organ. Here we present our clinical experience with anidulafungin for the treatment of documented nosocomial candidaemia.
FALCONE, MARCO, A. Russo, F. G. De Rosa, D. Pasero, Luigi Toma, RAPONI, Giammarco, GHEZZI, Maria Cristina, VENDITTI, Mario   +7 more
openaire   +4 more sources

Anidulafungine in clinical practice

2012
n ...
openaire   +2 more sources

Anidulafungin and Fluconazole for Candidiasis

New England Journal of Medicine, 2007
James M. O'Brien, Scott K. Aberegg
openaire   +3 more sources

Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program

Antimicrobial Agents and Chemotherapy, 2021
Lalitagauri M Deshpande, Paul R Rhomberg, Mariana Castanheira   +2 more
exaly  

MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method

Journal of Antimicrobial Chemotherapy, 2020
Andrew M Borman, Mark Fraser, Elizabeth M Johnson   +2 more
exaly  

Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia

Antimicrobial Agents and Chemotherapy, 2004
Annette Reboli
exaly